| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,630,000,000 |
| Market
Cap: |
384.35(B) |
| Last
Volume: |
6,182,604 |
Avg
Vol: |
8,314,942 |
| 52
Week Range: |
$144.45 - $174.48 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
| |
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
| |
MAJOR MARKET |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 21 |
| Guru Rank Value : 20.3 |
| Guru Occurances : 6 |
|
|
|
|
|
| |
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
68,288 |
68,288 |
115,451 |
522,170 |
| Total Sell Value |
$10,723,734 |
$10,723,734 |
$18,652,688 |
$88,845,171 |
| Total People Sold |
2 |
2 |
5 |
10 |
| Total Sell Transactions |
2 |
2 |
5 |
24 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,064 |
135,297 |
|
- |
|
| Duato Joaquin |
CEO |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$2,140,313 |
D/D |
(12,902) |
245,977 |
|
- |
|
| Duato Joaquin |
CEO |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,714 |
258,879 |
|
- |
|
| Wolk Joseph J |
Exec VP, CFO |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$1,214,149 |
D/D |
(7,319) |
35,858 |
|
- |
|
| Wolk Joseph J |
Exec VP, CFO |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,793 |
43,177 |
|
- |
|
| Wengel Kathryn E |
EVP, Chief GSC Officer |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$779,517 |
D/D |
(4,699) |
71,311 |
|
- |
|
| Wengel Kathryn E |
EVP, Chief GSC Officer |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,386 |
76,010 |
|
- |
|
| Mcevoy Ashley |
EVP, WW Chair, Medical Devices |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$1,035,485 |
D/D |
(6,242) |
41,813 |
|
- |
|
| Mcevoy Ashley |
EVP, WW Chair, Medical Devices |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,806 |
48,055 |
|
- |
|
| Mammen Mathai |
EVP, Pharm, R&D |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$558,386 |
D/D |
(3,366) |
41,934 |
|
- |
|
| Mammen Mathai |
EVP, Pharm, R&D |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,740 |
45,300 |
|
- |
|
| Broadhurst Vanessa |
EVP, Global Corp Aff. |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$153,448 |
D/D |
(925) |
15,667 |
|
- |
|
| Broadhurst Vanessa |
EVP, Global Corp Aff. |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,557 |
16,592 |
|
- |
|
| Mongon Thibaut |
Exec VP, WW Chair, Consumer |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$305,735 |
D/D |
(1,843) |
43,903 |
|
- |
|
| Mongon Thibaut |
Exec VP, WW Chair, Consumer |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,922 |
45,746 |
|
- |
|
| Gorsky Alex |
Director |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$4,391,440 |
D/D |
(26,472) |
585,447 |
|
- |
|
| Gorsky Alex |
Director |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,965 |
611,919 |
|
- |
|
| Adamczyk Darius |
Director |
– • – |
2022-02-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,063 |
|
9% |
|
| Hait William |
See Remarks |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$689,771 |
D/D |
(4,158) |
80,236 |
|
- |
|
| Hait William |
See Remarks |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,128 |
84,394 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2022-02-14 |
4 |
D |
$165.89 |
$848,361 |
D/D |
(5,114) |
114,676 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2022-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,154 |
118,497 |
|
- |
|
| Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
• • – |
2022-02-14 |
4 |
D |
$168.85 |
$200,932 |
D/D |
(1,190) |
117,233 |
|
- |
|
| Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
• • – |
2022-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,297 |
118,423 |
|
- |
|
| Mammen Mathai |
EVP, Pharm, R&D |
• • – |
2022-02-14 |
4 |
D |
$168.85 |
$394,265 |
D/D |
(2,335) |
37,560 |
|
- |
|
162 Records found
|
|
Page 5 of 7 |
|
|
0.68 (0.46%) 
